The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines Post published:January 5, 2022 Post category:Press Release
PharmaTher Announces Publication of Research Data for KETABET⢠Post published:January 4, 2022 Post category:Press Release
Filament Health Announces Health Canada Approval for Phase II Trial Administering New Psilocybin Microdose Formulation Post published:January 4, 2022 Post category:Press Release
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders Post published:January 4, 2022 Post category:Press Release
MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs’ Licensing Pathway Post published:January 4, 2022 Post category:Press Release
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC Post published:January 4, 2022 Post category:Press Release
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology Post published:January 4, 2022 Post category:Press Release
Psychedelic Bulletin: First Look at Field Trip’s FT-104 Molecule; MindMed Trial Halted by FDA, Changes at the Top Post published:December 31, 2021 Post category:Psychedelic Bulletin
MindMed Announces Transitions to Management Team Post published:December 29, 2021 Post category:Press Release